Disney+ vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global entertainment giant with $91.4B FY2024 revenue; Disney+ profitable 2024; Hulu 100% owned; ESPN DTC launch planned 2025; Experiences/parks at record levels; Peltz proxy fight won.
About
The Walt Disney Company is one of the world's largest entertainment and media conglomerates, founded in 1923 by Walt and Roy Disney in Los Angeles and now headquartered in Burbank, California, trading on NYSE (DIS). The company reported approximately $91.4 billion in revenues for fiscal year 2024 (ending September 28) under CEO Bob Iger, who returned to lead the company in November 2022 following a turbulent period under Bob Chapek. Iger's second tenure has focused on restoring Disney's creative culture, achieving streaming profitability, and restructuring the linear television portfolio as cord-cutting accelerates. Disney+ achieved its first quarterly profitability milestone in late 2023 and sustained profitability through FY2024, while ESPN's eventual direct-to-consumer streaming launch—planned for fall 2025—represents the most consequential strategic transition in Disney's recent history.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.